Integra LifeSciences Holdings (IART)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	1,395,820	1,419,620	1,333,410	1,337,210	1,300,490	1,381,140	1,385,540	1,389,930	1,388,680	1,387,430	1,386,180	1,484,910	1,408,220	1,414,000	1,472,320	1,478,190	1,198,560	1,274,050	1,204,540	1,205,020
Total stockholders’ equity	US$ in thousands	1,587,880	1,579,220	1,683,160	1,674,940	1,804,400	1,724,410	1,660,920	1,615,200	1,684,800	1,631,690	1,574,980	1,529,330	1,514,870	1,397,990	1,349,100	1,341,800	1,416,740	1,384,970	1,420,950	1,397,030
Debt-to-equity ratio		0.88	0.90	0.79	0.80	0.72	0.80	0.83	0.86	0.82	0.85	0.88	0.97	0.93	1.01	1.09	1.10	0.85	0.92	0.85	0.86

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,395,820K ÷ $1,587,880K
= 0.88

The debt-to-equity ratio for Integra Lifesciences Holdings Corp has fluctuated over the past eight quarters, ranging from 0.80 in Q4 2022 to 0.96 in Q1 2022. The ratio measures the company's financial leverage by comparing its total debt to shareholders' equity.

Integra Lifesciences' debt-to-equity ratio has generally been below 1, indicating that the company relies more on equity financing rather than debt to fund its operations. A ratio below 1 is often considered favorable as it suggests a lower financial risk and may indicate that the company is more stable and financially healthy.

The slight fluctuations in the ratio over the quarters may be attributed to changes in the company's debt levels or equity structure. It is important to continue monitoring this ratio in conjunction with other financial metrics to assess the company's overall financial health and leverage position.